Neuroscience Antibodies are major tools to clarify the process and mechanism which take place during neural development and related disease. The key to neuroscience research is the identification of cellular, molecular and tissue features that can be used as biomarkers to help identify patients at risk for neurological disease and as targets for new therapies.
The global market for Neuroscience Antibody was estimated to be worth US$ 3370 million in 2023 and is forecast to a readjusted size of US$ 5633.8 million by 2030 with a CAGR of 7.7% during the forecast period 2024-2030
The global neuroscience antibody market refers to the market for antibodies used in neuroscience research and diagnostics. Antibodies are essential tools for studying the structure, function, and interactions of proteins in the brain and nervous system.
Neuroscience research plays a critical role in understanding the complexities of the brain and nervous system, as well as in developing effective treatments for neurological disorders and diseases such as Alzheimer鈥檚 disease, Parkinson鈥檚 disease, multiple sclerosis, and depression. Antibodies are widely used in techniques such as immunohistochemistry, immunocytochemistry, Western blotting, and enzyme-linked immunosorbent assay (ELISA) for the detection and analysis of specific protein targets.
The market for neuroscience antibodies is driven by several factors. Firstly, the increasing prevalence of neurological disorders and the growing elderly population worldwide are fueling the demand for research and diagnostic tools. Neuroscience antibodies play a fundamental role in identifying biomarkers, studying disease mechanisms, and developing targeted therapies.
Secondly, technological advancements in antibody development and conjugation techniques have expanded the range of applications and improved the specificity and sensitivity of neuroscience antibodies. This has led to increased adoption and demand for these antibodies in both academic and pharmaceutical research settings.
Thirdly, government and private funding initiatives aimed at promoting neuroscience research and drug discovery programs have further contributed to the growth of the neuroscience antibody market. Increased funding allows for more extensive research projects and the development of new antibodies targeting specific protein markers associated with neurological disorders.
The market for neuroscience antibodies is segmented based on the type of antibody, including monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are highly specific and are commonly used for targeted detection and analysis of protein markers. Polyclonal antibodies, on the other hand, exhibit a broader range of binding affinities and are often used for screening and initial characterization purposes.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America has been a significant market for neuroscience antibodies due to the presence of well-established research institutions, pharmaceutical companies, and government support for neuroscience research. The Asia Pacific region is expected to witness significant market growth due to the increasing focus on neuroscience research and rising healthcare investments.
Key players in the global neuroscience antibody market include manufacturers specializing in antibody production, as well as biotechnology and pharmaceutical companies involved in neuroscience research and drug discovery. These companies offer a wide range of neuroscience antibodies targeting various protein markers and provide customization services to meet specific research needs. Collaboration with researchers and academia, as well as strategic mergers and acquisitions, are common strategies employed by key players to expand their market presence.
In summary, the global neuroscience antibody market is driven by factors such as the increasing prevalence of neurological disorders, technological advancements in antibody development, and research funding initiatives. Monoclonal and polyclonal antibodies are the two major types of antibodies used in neuroscience research. With ongoing advancements and the increasing focus on understanding the complexities of the brain, the neuroscience antibody market is expected to grow, providing valuable tools for researchers and contributing to advancements in neurological disease treatment and diagnostics.The global neuroscience antibody market refers to the market for antibodies used in neuroscience research and diagnostics. Antibodies are essential tools for studying the structure, function, and interactions of proteins in the brain and nervous system.
Neuroscience research plays a critical role in understanding the complexities of the brain and nervous system, as well as in developing effective treatments for neurological disorders and diseases such as Alzheimer鈥檚 disease, Parkinson鈥檚 disease, multiple sclerosis, and depression. Antibodies are widely used in techniques such as immunohistochemistry, immunocytochemistry, Western blotting, and enzyme-linked immunosorbent assay (ELISA) for the detection and analysis of specific protein targets.
The market for neuroscience antibodies is driven by several factors. Firstly, the increasing prevalence of neurological disorders and the growing elderly population worldwide are fueling the demand for research and diagnostic tools. Neuroscience antibodies play a fundamental role in identifying biomarkers, studying disease mechanisms, and developing targeted therapies.
Secondly, technological advancements in antibody development and conjugation techniques have expanded the range of applications and improved the specificity and sensitivity of neuroscience antibodies. This has led to increased adoption and demand for these antibodies in both academic and pharmaceutical research settings.
Thirdly, government and private funding initiatives aimed at promoting neuroscience research and drug discovery programs have further contributed to the growth of the neuroscience antibody market. Increased funding allows for more extensive research projects and the development of new antibodies targeting specific protein markers associated with neurological disorders.
The market for neuroscience antibodies is segmented based on the type of antibody, including monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are highly specific and are commonly used for targeted detection and analysis of protein markers. Polyclonal antibodies, on the other hand, exhibit a broader range of binding affinities and are often used for screening and initial characterization purposes.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America has been a significant market for neuroscience antibodies due to the presence of well-established research institutions, pharmaceutical companies, and government support for neuroscience research. The Asia Pacific region is expected to witness significant market growth due to the increasing focus on neuroscience research and rising healthcare investments.
Key players in the global neuroscience antibody market include manufacturers specializing in antibody production, as well as biotechnology and pharmaceutical companies involved in neuroscience research and drug discovery. These companies offer a wide range of neuroscience antibodies targeting various protein markers and provide customization services to meet specific research needs. Collaboration with researchers and academia, as well as strategic mergers and acquisitions, are common strategies employed by key players to expand their market presence.
In summary, the global neuroscience antibody market is driven by factors such as the increasing prevalence of neurological disorders, technological advancements in antibody development, and research funding initiatives. Monoclonal and polyclonal antibodies are the two major types of antibodies used in neuroscience research. With ongoing advancements and the increasing focus on understanding the complexities of the brain, the neuroscience antibody market is expected to grow, providing valuable tools for researchers and contributing to advancements in neurological disease treatment and diagnostics.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroscience Antibody, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuroscience Antibody by region & country, by Type, and by Application.
The Neuroscience Antibody market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroscience Antibody.
麻豆原创 Segmentation
By Company
Abcam
BioLegend
Bio-Rad Laboratories Inc
Cell Signaling Technology
Roche
Genscript Biotech Corp
Merck KGaA
Rockland Immunochemicals Inc
Santa Cruz Biotechnology Inc
Siemens Healthineers
Tecan Group Ltd
Thermo Fisher Scientific Inc
Enzo Life Sciences AG
Neobioscience
Segment by Type:
Antibodies
Research Reagents
Segment by Application
Hospitals and Diagnostics Centers
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuroscience Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuroscience Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuroscience Antibody in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Neuroscience Antibody Product Introduction
1.2 Global Neuroscience Antibody 麻豆原创 Size Forecast
1.2.1 Global Neuroscience Antibody Sales Value (2019-2030)
1.2.2 Global Neuroscience Antibody Sales Volume (2019-2030)
1.2.3 Global Neuroscience Antibody Sales Price (2019-2030)
1.3 Neuroscience Antibody 麻豆原创 Trends & Drivers
1.3.1 Neuroscience Antibody Industry Trends
1.3.2 Neuroscience Antibody 麻豆原创 Drivers & Opportunity
1.3.3 Neuroscience Antibody 麻豆原创 Challenges
1.3.4 Neuroscience Antibody 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuroscience Antibody Players Revenue Ranking (2023)
2.2 Global Neuroscience Antibody Revenue by Company (2019-2024)
2.3 Global Neuroscience Antibody Players Sales Volume Ranking (2023)
2.4 Global Neuroscience Antibody Sales Volume by Company Players (2019-2024)
2.5 Global Neuroscience Antibody Average Price by Company (2019-2024)
2.6 Key Manufacturers Neuroscience Antibody Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Neuroscience Antibody Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Neuroscience Antibody
2.9 Neuroscience Antibody 麻豆原创 Competitive Analysis
2.9.1 Neuroscience Antibody 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Neuroscience Antibody Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroscience Antibody as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antibodies
3.1.2 Research Reagents
3.2 Global Neuroscience Antibody Sales Value by Type
3.2.1 Global Neuroscience Antibody Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neuroscience Antibody Sales Value, by Type (2019-2030)
3.2.3 Global Neuroscience Antibody Sales Value, by Type (%) (2019-2030)
3.3 Global Neuroscience Antibody Sales Volume by Type
3.3.1 Global Neuroscience Antibody Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Neuroscience Antibody Sales Volume, by Type (2019-2030)
3.3.3 Global Neuroscience Antibody Sales Volume, by Type (%) (2019-2030)
3.4 Global Neuroscience Antibody Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals and Diagnostics Centers
4.1.2 Academic and Research Institutes
4.1.3 Pharmaceutical and Biotechnology Companies
4.2 Global Neuroscience Antibody Sales Value by Application
4.2.1 Global Neuroscience Antibody Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neuroscience Antibody Sales Value, by Application (2019-2030)
4.2.3 Global Neuroscience Antibody Sales Value, by Application (%) (2019-2030)
4.3 Global Neuroscience Antibody Sales Volume by Application
4.3.1 Global Neuroscience Antibody Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Neuroscience Antibody Sales Volume, by Application (2019-2030)
4.3.3 Global Neuroscience Antibody Sales Volume, by Application (%) (2019-2030)
4.4 Global Neuroscience Antibody Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Neuroscience Antibody Sales Value by Region
5.1.1 Global Neuroscience Antibody Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neuroscience Antibody Sales Value by Region (2019-2024)
5.1.3 Global Neuroscience Antibody Sales Value by Region (2025-2030)
5.1.4 Global Neuroscience Antibody Sales Value by Region (%), (2019-2030)
5.2 Global Neuroscience Antibody Sales Volume by Region
5.2.1 Global Neuroscience Antibody Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Neuroscience Antibody Sales Volume by Region (2019-2024)
5.2.3 Global Neuroscience Antibody Sales Volume by Region (2025-2030)
5.2.4 Global Neuroscience Antibody Sales Volume by Region (%), (2019-2030)
5.3 Global Neuroscience Antibody Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Neuroscience Antibody Sales Value, 2019-2030
5.4.2 North America Neuroscience Antibody Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Neuroscience Antibody Sales Value, 2019-2030
5.5.2 Europe Neuroscience Antibody Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Neuroscience Antibody Sales Value, 2019-2030
5.6.2 Asia Pacific Neuroscience Antibody Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Neuroscience Antibody Sales Value, 2019-2030
5.7.2 South America Neuroscience Antibody Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Neuroscience Antibody Sales Value, 2019-2030
5.8.2 Middle East & Africa Neuroscience Antibody Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuroscience Antibody Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neuroscience Antibody Sales Value
6.2.1 Key Countries/Regions Neuroscience Antibody Sales Value, 2019-2030
6.2.2 Key Countries/Regions Neuroscience Antibody Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Neuroscience Antibody Sales Value, 2019-2030
6.3.2 United States Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neuroscience Antibody Sales Value, 2019-2030
6.4.2 Europe Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neuroscience Antibody Sales Value, 2019-2030
6.5.2 China Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neuroscience Antibody Sales Value, 2019-2030
6.6.2 Japan Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neuroscience Antibody Sales Value, 2019-2030
6.7.2 South Korea Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neuroscience Antibody Sales Value, 2019-2030
6.8.2 Southeast Asia Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neuroscience Antibody Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neuroscience Antibody Sales Value, 2019-2030
6.9.2 India Neuroscience Antibody Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neuroscience Antibody Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abcam
7.1.1 Abcam Company Information
7.1.2 Abcam Introduction and Business Overview
7.1.3 Abcam Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Abcam Neuroscience Antibody Product Offerings
7.1.5 Abcam Recent Development
7.2 BioLegend
7.2.1 BioLegend Company Information
7.2.2 BioLegend Introduction and Business Overview
7.2.3 BioLegend Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.2.4 BioLegend Neuroscience Antibody Product Offerings
7.2.5 BioLegend Recent Development
7.3 Bio-Rad Laboratories Inc
7.3.1 Bio-Rad Laboratories Inc Company Information
7.3.2 Bio-Rad Laboratories Inc Introduction and Business Overview
7.3.3 Bio-Rad Laboratories Inc Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Bio-Rad Laboratories Inc Neuroscience Antibody Product Offerings
7.3.5 Bio-Rad Laboratories Inc Recent Development
7.4 Cell Signaling Technology
7.4.1 Cell Signaling Technology Company Information
7.4.2 Cell Signaling Technology Introduction and Business Overview
7.4.3 Cell Signaling Technology Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Cell Signaling Technology Neuroscience Antibody Product Offerings
7.4.5 Cell Signaling Technology Recent Development
7.5 Roche
7.5.1 Roche Company Information
7.5.2 Roche Introduction and Business Overview
7.5.3 Roche Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Roche Neuroscience Antibody Product Offerings
7.5.5 Roche Recent Development
7.6 Genscript Biotech Corp
7.6.1 Genscript Biotech Corp Company Information
7.6.2 Genscript Biotech Corp Introduction and Business Overview
7.6.3 Genscript Biotech Corp Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Genscript Biotech Corp Neuroscience Antibody Product Offerings
7.6.5 Genscript Biotech Corp Recent Development
7.7 Merck KGaA
7.7.1 Merck KGaA Company Information
7.7.2 Merck KGaA Introduction and Business Overview
7.7.3 Merck KGaA Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Merck KGaA Neuroscience Antibody Product Offerings
7.7.5 Merck KGaA Recent Development
7.8 Rockland Immunochemicals Inc
7.8.1 Rockland Immunochemicals Inc Company Information
7.8.2 Rockland Immunochemicals Inc Introduction and Business Overview
7.8.3 Rockland Immunochemicals Inc Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Rockland Immunochemicals Inc Neuroscience Antibody Product Offerings
7.8.5 Rockland Immunochemicals Inc Recent Development
7.9 Santa Cruz Biotechnology Inc
7.9.1 Santa Cruz Biotechnology Inc Company Information
7.9.2 Santa Cruz Biotechnology Inc Introduction and Business Overview
7.9.3 Santa Cruz Biotechnology Inc Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Santa Cruz Biotechnology Inc Neuroscience Antibody Product Offerings
7.9.5 Santa Cruz Biotechnology Inc Recent Development
7.10 Siemens Healthineers
7.10.1 Siemens Healthineers Company Information
7.10.2 Siemens Healthineers Introduction and Business Overview
7.10.3 Siemens Healthineers Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Siemens Healthineers Neuroscience Antibody Product Offerings
7.10.5 Siemens Healthineers Recent Development
7.11 Tecan Group Ltd
7.11.1 Tecan Group Ltd Company Information
7.11.2 Tecan Group Ltd Introduction and Business Overview
7.11.3 Tecan Group Ltd Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Tecan Group Ltd Neuroscience Antibody Product Offerings
7.11.5 Tecan Group Ltd Recent Development
7.12 Thermo Fisher Scientific Inc
7.12.1 Thermo Fisher Scientific Inc Company Information
7.12.2 Thermo Fisher Scientific Inc Introduction and Business Overview
7.12.3 Thermo Fisher Scientific Inc Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Thermo Fisher Scientific Inc Neuroscience Antibody Product Offerings
7.12.5 Thermo Fisher Scientific Inc Recent Development
7.13 Enzo Life Sciences AG
7.13.1 Enzo Life Sciences AG Company Information
7.13.2 Enzo Life Sciences AG Introduction and Business Overview
7.13.3 Enzo Life Sciences AG Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Enzo Life Sciences AG Neuroscience Antibody Product Offerings
7.13.5 Enzo Life Sciences AG Recent Development
7.14 Neobioscience
7.14.1 Neobioscience Company Information
7.14.2 Neobioscience Introduction and Business Overview
7.14.3 Neobioscience Neuroscience Antibody Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Neobioscience Neuroscience Antibody Product Offerings
7.14.5 Neobioscience Recent Development
8 Industry Chain Analysis
8.1 Neuroscience Antibody Industrial Chain
8.2 Neuroscience Antibody Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuroscience Antibody Sales Model
8.5.2 Sales Channel
8.5.3 Neuroscience Antibody Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Abcam
BioLegend
Bio-Rad Laboratories Inc
Cell Signaling Technology
Roche
Genscript Biotech Corp
Merck KGaA
Rockland Immunochemicals Inc
Santa Cruz Biotechnology Inc
Siemens Healthineers
Tecan Group Ltd
Thermo Fisher Scientific Inc
Enzo Life Sciences AG
Neobioscience
听
听
*If Applicable.
